Brought to you by 
Eli Lilly gets rights to Marcadia's glucagon analog program
29 Jun 2010
Executive Summary
Marcadia Biotech Inc. (developing therapeutics for obesity and diabetes) has licensed Eli Lilly & Co. exclusive global marketing rights to its preclinical short-acting glucagon analog MAR531 and backup compounds for hypoglycemia.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eli Lilly gets rights to Marcadia's glucagon analog program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice